Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Virax Biolabs Group Ltd. has partnered with French company Tebubio to distribute its ImmuneSelect portfolio across the European Union, Norway, and Switzerland. This collaboration aims to enhance the accessibility of ImmuneSelect products, which are crucial for researching adaptive immunity. The products, optimized for stimulating T cells, are intended for research use and not for diagnostic purposes.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.
